ArticleFrontiers in physiology2022
Editorial: Diminished Ovarian Reserve and Poor Ovarian Response: Diagnostic and Therapeutic Management.
Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial.Journal of ovarian research · 2024Trial
- Shift Work as a Potential Risk Factor for Lower Ovarian Reserve: A Study of Fertility Patients.Journal of clinical medicine · 2026Article
- IGF-1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pathogenic mechanisms and comprehensive therapeutic strategies of ovarian aging: targeting gut microbiota.Frontiers in microbiology · 2026Review
- Efficacy of follitropin delta in potential low responders: a pooled analysis of individual patient data from five randomized controlled trials.Frontiers in endocrinology · 2026Article
- Identify high-risk DOR women ≤ 35 years old following assisted reproduction technology through cutoffs of anti-mullerian hormone and antral follicle counts.Reproductive biology and endocrinology : RB&E · 2024Article
- The effects of growth hormone on the outcomes ofFrontiers in endocrinology · 2024Article
- Paeoniflorin Alleviates Cisplatin-Induced Diminished Ovarian Reserve by Restoring the Function of Ovarian Granulosa Cells via Activating FSHR/cAMP/PKA/CREB Signaling Pathway.Molecules (Basel, Switzerland) · 2023Article
- Mitochondria in reproduction.Clinical and experimental reproductive medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.